Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BBIBP-CorV

Vaccine (Inactivated vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by China National Biotec Group Company

Phase 3 Most advanced trial (none active)

1 Registered trials

What is BBIBP-CorV?

BBIBP-CorV is an inactivated SARS-CoV-2 vaccine adjuvanted with aluminum hydroxide. It induces neutralizing antibodies against SARS-CoV-2 to provide protection against infection. The vaccine is studied in COVID-19 prevention.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Inactivated vaccine)
Targets: SARS-CoV-2 spike protein (antigen)
Mechanism: Immune activation, directed at SARS-CoV-2 spike protein
Pathways: immune_activation
Therapy area: Infectious disease
Developer: China National Biotec Group Company Limited
In trials of: NVAX
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05249816	Phase 3	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	Completed	NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z